Sensei biotherapeutics presents new preclinical data on sns-103 targeting entpdase1 (cd39) at the american association for cancer research (aacr) annual meeting 2023

Boston, april 18, 2023 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today presented new preclinical data on its sns-103 program aimed at developing a conditionally active, monoclonal antibody program targeting entpdase1 (also known as cd39) at the american association for cancer research (aacr) annual meeting 2023.
SNSE Ratings Summary
SNSE Quant Ranking